Phocas Financial Corp. Sells 16,348 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Phocas Financial Corp. trimmed its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 85.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,885 shares of the biopharmaceutical company’s stock after selling 16,348 shares during the quarter. Phocas Financial Corp.’s holdings in Intra-Cellular Therapies were worth $241,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. TimesSquare Capital Management LLC grew its stake in shares of Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock valued at $70,179,000 after purchasing an additional 402,186 shares during the last quarter. Eagle Asset Management Inc. grew its stake in shares of Intra-Cellular Therapies by 130.5% during the third quarter. Eagle Asset Management Inc. now owns 624,759 shares of the biopharmaceutical company’s stock valued at $45,714,000 after purchasing an additional 353,723 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Intra-Cellular Therapies by 9.7% during the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock valued at $129,463,000 after purchasing an additional 155,655 shares during the last quarter. Wasatch Advisors LP grew its stake in shares of Intra-Cellular Therapies by 3.5% during the third quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock valued at $281,601,000 after purchasing an additional 130,351 shares during the last quarter. Finally, M&G PLC bought a new stake in shares of Intra-Cellular Therapies during the third quarter valued at approximately $9,076,000. 92.33% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Sharon Mates sold 51,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.60% of the stock is currently owned by company insiders.

Intra-Cellular Therapies Stock Down 0.1 %

Shares of NASDAQ:ITCI opened at $128.46 on Thursday. Intra-Cellular Therapies, Inc. has a 12 month low of $63.30 and a 12 month high of $129.00. The company’s fifty day simple moving average is $111.97 and its 200 day simple moving average is $90.60. The firm has a market cap of $13.66 billion, a price-to-earnings ratio of -147.65 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a report on Monday. They issued a “hold” rating on the stock. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Ten equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Intra-Cellular Therapies presently has an average rating of “Hold” and a consensus target price of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.